NEW DRUG FIGHTS BACTERIAL INFECTIONS IN NOVEL WAY.
Over the course of the 20th Century, doctors waged war against
infectious bacterial illness with the best new weapon they had:
antibiotics.
But the emergence of dangerous, multi-drug resistant . . .
BREAKTHROUGH FOR CANCER PAIN.
Not every breakthrough is positive. Of the approximately 1.4
million new cancer patients in the U.S. each year, more than half
experience pain associated with their disease. The patient's level
of . . .
U.S. AWARDS $15 MIL TO GEOVAX HIV/AIDS VACCINE PROGRAM.
GeoVax Labs, Inc. (OTC BB:GOVX), an Atlanta based biotechnology
company, has announced receipt of an estimated $15,000,000 Integrated
Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant to . . .
ENCOURAGING PHASE II DATA ON GENVEC HIV VACCINE.
GenVec, Inc. (Nasdaq:GNVC), Gaithersburg, Md., has announced that
results from multiple ongoing clinical trials utilizing its adenovector
vaccine technologies were presented at the AIDS Vaccine . . .
MIT MODEL COULD PREDICT CELL'S RESPONSE TO DRUGS.
MIT researchers have developed a model that could predict how cells
will respond to targeted drug therapies. Models based on this approach
could help doctors make better treatment choices for . . .
FDA GIVES TENTATIVE APPROVAL OF STAVZOR.
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN), Miami, Fla., announced
that the U.S. Food and Drug Administration (FDA) has issued a tentative
approval letter related to the New Drug Application (NDA) . . .
OSTEOPOROSIS: AN EQUAL OPORTUNITY ILLNESS.
Osteoporosis is traditionally thought of as a women's disease,
however, it also poses a significant threat to men. According to the
National Osteoporosis Foundation, twelve million men are at risk . . .
NOVABAY REPORTS POSITIVE PHASE I AGANOCIDE RESULTS FOR
MRSA.
NovaBay Pharmaceuticals, Inc., Emeryville, Calif., (AMEX & TSX:
NBY, http://novabaypharma.com), a biopharmaceutical company developing
products for the treatment or prevention of a wide range of . . .
BIOGEN IDEC/JOHNS HOPKINS TO DEVELOP NEURODEGENERATIVE
THERAPIES.
Biogen Idec (NASDAQ: BIIB), Cambridge, Mass, has announced a
research collaboration with the newly formed Brain Science Institute at
Johns Hopkins University to discover and develop therapies . . .
ADVANCED LIFE SCIENCES TO STUDY CETHROMYCIN FOR ANTHRAX.
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), Chicago, has
announced the commencement of its collaboration with the National
Institute of Allergy and Infectious Diseases (NIAID), the . . .
ADOLOR SUBMITS ADL5747 IND FOR DELTA OPIOID RECEPTOR
TARGET.
Adolor Corporation, Exton, Pa., (Nasdaq:ADLR) has announced that
clinical testing will be permitted under an Investigational New Drug
Application (IND) for ADL5747, a novel oral compound that . . .
UCB FILES NDA FOR LACOSAMIDE FOR DIABETIC NEUROPATHIC
PAIN.
UCB has announced that the FDA has accepted for filing the New Drug
Application (NDA) for the use of lacosamide in the treatment of diabetic
neuropathic pain. The application relates to the tablet . . .
MILLIPORE/ABEOME TO DISTRIBUTE STEM CELL ANTIBODY.(Company
overview)
Millipore Corporation, Billerica, Mass., a Life Science leader
providing technologies, tools and services for the bioscience research
and biopharmaceutical manufacturing industry, announced . . .
AETHLON ANNOUNCES BIRD FLU RESEARCH COLLABORATIONS.
Aethlon Medical, Inc., (OTCBB:AEMD),San Diego, will initiate
research studies to test the in vitro effectiveness of the Aethlon
Hemopurifier(R) to capture H5N1 Avian Influenza. Testing of . . .
GENTA STARTS PHASE 3 AGENDA TRIAL OF GENASENSE FOR
MELANOMA.
Genta Incorporated (Nasdaq:GNTA), Berkeley Heights, N.J., has
announced that the first patients have been enrolled in the
company's confirmatory Phase 3 trial of Genasense(r) (oblimersen
sodium) . . .
IMMUNEREGEN/DELSITE COLLABORATE ON NEW FLU TREATMENT.
ImmuneRegen(r) BioSciences, Inc., Scottsdale, Ariz., a wholly owned
biotechnology product development and licensing subsidiary of IR
BioSciences Holdings, Inc. (OTCBB:IRBO), has commenced a . . .
POSITIVE PRECLINICAL RESULTS FROM TOPICAL ZYBRESTAT.
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), Waltham, Mass., a
clinical-stage, biopharmaceutical company developing novel therapeutics
to treat cancer and eye diseases, has reported positive results . . .
NYMOX REPORTS POSITIVE RESULTS FOR 2 YEAR NX-1207 BPH
STUDY.(Clinical report)
Nymox Pharmaceutical Corporation (NASDAQ: NYMX), Hasbrouck,
Heights, N.J., has announced positive results from a newly completed
long-term outcome study of NX-1207 for benign prostatic . . .
NIH AWARDS PHARMATHENE UP TO $13.9 MIL FOR ANTHRAX
ANTI-TOXIN.
PharmAthene, Inc. (AMEX: PIP), a biodefense company developing
medical countermeasures against biological and chemical threats, and
Medarex, Inc. (Nasdaq: MEDX), a leading monoclonal antibody . . .
QUATRX ENROLLS OPHENA PHASE 3 FOR POSTMENOPAUSAL
SYNDROME.
QuatRx Pharmaceuticals, Ann Arbor, Mich., a privately-held
biopharmaceutical company focused on development and commercialization
of compounds to treat endocrine, metabolic and cardiovascular . . .
|
|